These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8956684)

  • 101. Shifts in covert visual attention in schizophrenic patients and normal controls.
    Moran MJ; Thaker GK; Smith D; Cassady S; Layne-Gedge J
    Biol Psychiatry; 1992 Oct; 32(7):617-20. PubMed ID: 1450288
    [No Abstract]   [Full Text] [Related]  

  • 102. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Sleep onset REM periods in schizophrenic patients.
    Taylor SF; Tandon R; Shipley JE; Eiser AS; Goodson J
    Biol Psychiatry; 1991 Jul; 30(2):205-9. PubMed ID: 1912111
    [No Abstract]   [Full Text] [Related]  

  • 104. A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients.
    Kurland AA; Nagaraju A; Hanlon TE; Wilkinson EH; Ng KT
    J Clin Pharmacol; 1981 Jan; 21(1):42-7. PubMed ID: 7217342
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Reduced status of plasma total antioxidant capacity in schizophrenia.
    Yao JK; Reddy R; McElhinny LG; van Kammen DP
    Schizophr Res; 1998 Jun; 32(1):1-8. PubMed ID: 9690328
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.
    Czobor P; Volavka J
    Psychiatry Res; 1992 May; 42(2):129-44. PubMed ID: 1631250
    [TBL] [Abstract][Full Text] [Related]  

  • 107. 3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects.
    Wodarz N; Fritze J; Riederer P; Beckmann H
    Biol Psychiatry; 1993 May; 33(10):727-33. PubMed ID: 8353168
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.
    Kidron R; Averbuch I; Klein E; Belmaker RH
    Biol Psychiatry; 1985 Feb; 20(2):219-22. PubMed ID: 3971003
    [No Abstract]   [Full Text] [Related]  

  • 109. Acutely administered haloperidol has little effect on steady-state visual evoked potentials from pattern-reversal stimulations in treated schizophrenics.
    Jibiki I; Kurokawa K; Fukushima T; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Mar; 47(1):51-5. PubMed ID: 8411790
    [TBL] [Abstract][Full Text] [Related]  

  • 110. QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients.
    Galderisi S; Maj M; Mucci A; Bucci P; Kemali D
    Biol Psychiatry; 1994 Mar; 35(6):367-74. PubMed ID: 8018782
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Beneficial effects of gonadotropin-releasing hormone analogue treatment on positive and negative symptoms of schizophrenia: a case report.
    Soreni N; Weizman A; Weiss M
    J Clin Psychiatry; 2004 Jul; 65(7):1020-1. PubMed ID: 15291698
    [No Abstract]   [Full Text] [Related]  

  • 112. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.
    Rubin RT; Forsman A; Heykants J; Ohman R; Tower B; Michiels M
    Arch Gen Psychiatry; 1980 Sep; 37(9):1069-74. PubMed ID: 7416906
    [TBL] [Abstract][Full Text] [Related]  

  • 114. A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics.
    Lévy-Soussan P; Barbouche R; Poirier MF; Galinowski A; Lôo H; Avrameas S
    Biol Psychiatry; 1994 Jan; 35(2):135-8. PubMed ID: 8167210
    [No Abstract]   [Full Text] [Related]  

  • 115. The effect of haloperidol on aldosterone secretion.
    Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
    Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Haloperidol concentrations elevated in Chinese patients.
    Potkin SG; Shen Y; Pardes H; Phelps BH; Zhou D; Shu L; Korpi E; Wyatt RJ
    Psychiatry Res; 1984 Jun; 12(2):167-72. PubMed ID: 6591221
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
    Jann MW; Chang WH; Lam YW; Hwu HG; Lin HN; Chen H; Chen TY; Lin SK; Chien CP; Davis CM
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):193-202. PubMed ID: 1579637
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.
    Yao JK; van Kammen DP; Gurklis J
    Schizophr Res; 1994 Oct; 13(3):227-32. PubMed ID: 7841135
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The influence of cigarette smoking on haloperidol pharmacokinetics.
    Miller DD; Kelly MW; Perry PJ; Coryell WH
    Biol Psychiatry; 1990 Sep; 28(6):529-31. PubMed ID: 2223923
    [No Abstract]   [Full Text] [Related]  

  • 120. Measurement of haloperidol reductase activity in red blood cells and reduced haloperidol/haloperidol ratios in plasma in oriental psychiatric patients.
    Shibasaki M; Someya T; Kato T; Noguchi T; Ishida N; Takahashi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):941-7. PubMed ID: 2277853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.